AgnistaBio Inc
Biotechnology company using deep learning and high-performance computing to accelerate translational medicine and drug discovery. The organization develops computational platforms for protein structure and interactome prediction, discovers developable human antibodies and cyclic peptides from sequence data, and advances a preclinical portfolio of bio-better and peptide candidates through AI-driven selection and wet-lab validation. The company partners with pharma and biotech for licensing and co-development.
Industries
N/A
Products
Preclinical portfolio of antibody and cyclic peptide candidates
In-house R&D programs comprising bio-better antibodies and cyclic peptide candidates undergoing AI-driven optimization and staged validation (in vitro and in vivo). Timelines and estimated completion dates are provided for individual projects.
Preclinical portfolio of antibody and cyclic peptide candidates
In-house R&D programs comprising bio-better antibodies and cyclic peptide candidates undergoing AI-driven optimization and staged validation (in vitro and in vivo). Timelines and estimated completion dates are provided for individual projects.
Services
Partnering and co-development for therapeutic discovery
Licensing and co-development agreements to enable pharma/biotech partners to access AI platforms for antibody and peptide discovery and to co-develop therapeutic candidates.
Partnering and co-development for therapeutic discovery
Licensing and co-development agreements to enable pharma/biotech partners to access AI platforms for antibody and peptide discovery and to co-develop therapeutic candidates.
Expertise Areas
- AI-driven drug discovery
- Protein structure prediction and modeling
- Antibody discovery and engineering
- Cyclic peptide therapeutics
Key Technologies
- Deep learning-based protein structure prediction
- 4D protein-protein interaction modeling
- Antibody sequence discovery from amino acid sequences
- Cyclic peptide design